Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-189 Japan Extension: Pembrolizumab in NSCLC
NCT03950674Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2016
- Primary completion
- May 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + Chemo with Placebo + Chemo (2 arms). Primary endpoints: Progression-Free Survival at 31 months and Overall Survival at 31 months. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03950674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950674.